Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,796.00
(
0.00%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.40
(
3.58%
)
Bitcoin
70,053.72
(
-1.67%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: acgood post# 125935

Tuesday, 08/30/2011 11:40:30 PM

Tuesday, August 30, 2011 11:40:30 PM

Post# of 257257

Did your list mostly cut off due to scale/resources? Any of the next tier or other foreign firms have a compelling "pro" rationale?

Yes on both counts—some of the second-tier drug/biotech companies could conceivably be FoB partners, but I don’t think any of them individually is likely enough to try to handicap such deals.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today